Open AccessSequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion–Positive Metastatic Urothelial Carcinoma
Author(s) -
Amin H. Nassar,
Kevin Lundgren,
Jaegil Kim,
Toni K. Choueiri,
Guru Sonpavde,
David J. Kwiatkowski,
Joaquim Bellmunt
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00117
Subject(s) - atezolizumab , metastatic urothelial carcinoma , medicine , oncology , urothelial carcinoma , cancer research , immunotherapy , cancer , bladder cancer , pembrolizumab
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom